0001213900-18-006125.txt : 20180514 0001213900-18-006125.hdr.sgml : 20180514 20180514164656 ACCESSION NUMBER: 0001213900-18-006125 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20180514 DATE AS OF CHANGE: 20180514 EFFECTIVENESS DATE: 20180514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-224920 FILM NUMBER: 18831408 BUSINESS ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 646-677-3853 MAIL ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 S-8 1 fs82018_relmadatherap.htm REGISTRATION STATEMENT

As filed with the Securities and Exchange Commission on May 14, 2018 

Registration No.               

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

RELMADA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   45-5401931
(State or other Jurisdiction of   (I.R.S Employer
Incorporation or Organization)   Identification Number)
     
750 Third Avenue, 9th Floor, New York, NY   10017
(Address of Principal Executive Offices)   (Zip Code)

 

RELMADA THERAPEUTICS, INC.

2014 STOCK OPTION AND
EQUITY INCENTIVE PLAN

(Full Title of the Plan)

 

Sergio Traversa
Chief Executive Officer
750 Third Avenue, 9th Floor
New York, New York 10017
Phone: (212) 547-9591
(Name, Address and Telephone Number of Agent for Service)

 

Copy to:

Thomas Slusarczyk, Esq.

The Matt Law Firm, PLLC

1701 Genesee Street

Utica, New York 13501

(315) 235-2299

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☐   Smaller reporting company ☒
(Do not check if a smaller reporting company)   Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

  

CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered   Amount to be
registered (1)		     Proposed maximum
offering price
per share (2)		     Proposed maximum
aggregate offering
price (2)		     Amount of
registration
fee		  
Common Stock $0.001 par value (3)     5,000,000     $ 1.50     $ 7,500,000     $ 933.75  

 

(1) This Registration Statement also covers additional shares of Relmada Therapeutics, Inc. common stock that may be issuable by reason of stock splits, stock dividends, or other adjustment provisions of the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as amended, in accordance with Rule 416 under the Securities Act of 1933, as amended.

(2) Estimated solely for the purpose of calculating the registration fee computed pursuant to Rule 457(c) and (h), upon the basis of the average of the high and low prices of the common stock as quoted on the OTCQB on May 9, 2018.

(3) Represents the number of stock options and shares available for future option grants under the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan.

 

 

 

 

 

  

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed by Relmada Therapeutics, Inc. (the “Company”), pursuant to General Instruction E to the Form S-8 Registration Statement under the Securities Act of 1933, as amended, in connection with the registration of an additional 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable pursuant to the Company’s 2014 Stock Option and Equity Incentive Plan (as amended, the “Plan”). 1,611,769 shares of Common Stock issuable under the Plan have been previously registered pursuant to the Company’s Registration Statement on Form S-8 (File No. 333-207253) filed with the Securities and Exchange Commission on October 2, 2015, and the information contained therein is incorporated herein by reference.

 

 1 

 

   

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in accordance with Rule 428(b)(1) under the Securities Act.  In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. Such documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents filed by the Registrant with the Commission are incorporated herein by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

 

(a) The Registrant’s Annual Report on Form 10-K for the year ended June 30, 2017 filed with the Commission on September 28, 2017;

 

(b) The Registrant’s Quarterly Reports on Form 10-Q filed with the Commission on November 14. 2017, February 12, 2018 and May 14, 2018;

 

(c) The Registrant’s Current Reports on Form 8-K filed with the Commission on October 4, 2017, January 19, 2018, February 5, 2018, and April 2, 2018;

 

(d)  All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, subsequent to the end of the fiscal year covered by the form referred to in (a) above; and

 

(e) The description of our common stock, which is contained in our Form S-1, filed with the Securities and Exchange Commission on June 27, 2014, including any amendment or report filed for the purpose of updating such description.

 

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

 

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

 

 2 

 

 

You may request a copy of these filings, at no cost, by writing or telephoning the Registrant at:

 

750 Third Avenue

9th Floor

New York, NY 10017

Telephone: 212-547-9591

Attn: Investor Relations

 

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document. 

  

Item 8. Exhibits.

 

Exhibit No.   Description
3.1   Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 filed with the SEC on November 13, 2012).
3.2   Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Report on Form 8-K filed with the SEC on May 19, 2014).
3.3   Nevada Certificate of Amendment to Articles of Incorporation, effective May 30, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on May 27, 2014).
3.4   Nevada Certificate of Amendment to Articles of Incorporation, effective July 8, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on July 14, 2014).
3.5   Nevada Certificate of Amendment to Articles of Incorporation, effective February 12, 2015 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed with the SEC on February 13, 2015).
3.6   Nevada Certificate of Change Pursuant to NRS 78,209, effective August 11, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on August 10, 2015).
3.7   Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 of Relmada’s Form 8-K filed with the SEC on August 7, 2015).
4.1   Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 10, 2015).
5.1     Opinion of Fennemore Craig, P.C. *
23.1   Consent of GBH CPAs, PC *
23.2   Consent of Fennemore Craig, P.C. (included in Exhibit 5.1) *
24.1   Power of Attorney (included on signature page) *
99.1   Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.14 of Relmada’s Form S-1/A filed with the SEC on December 9, 2014).
99.2   Amended 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on August 7, 2015).
99.3   Amendment No. 2 to Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan  (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on February 2, 2017).
99.4   Third Amendment to the 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on May 14, 2018).

 

* Filed herewith

 

 3 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 14th day of May, 2018. 

 

  Relmada Therapeutics, Inc.
     
  By: /s/ Sergio Traversa
    Name: Sergio Traversa
    Title: Chief Executive Officer and Interim CFO
(Duly Authorized Officer, Principal Executive Officer, and Principal Financial and Accounting Officer)

 

POWER OF ATTORNEY

 

Each of the undersigned directors and officers of Relmada Therapeutics, Inc., a Nevada corporation, do hereby constitute and appoint Sergio Traversa the undersigned’s true and lawful attorney and agent, with full power of substitution and resubstitution in each, to do any and all acts and things in our name and on our behalf in our respective capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents, or either one of them, may deem necessary or advisable to enable said corporation to comply with the Securities Act, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this registration statement, including specifically, but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto, and each of the undersigned does hereby ratify and confirm all that said attorneys and agents, or either one of them or any substitute, shall do or cause to be done by virtue hereof. This Power of Attorney may be executed in any number of counterparts.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature   Title   Date
         
/s/ Sergio Traversa   Chief Executive Officer and Interim CFO   May 14, 2018
Sergio Traversa   (Principal Executive Officer and Principal Financial and Accounting Officer)    
         
/s/ Charles Casamento   Chairman of the Board   May 14, 2018
Charles Casamento        
         
/s/ Paul Kelly   Director   May 14, 2018
Paul Kelly        
         
/s/ Maged Shenouda   Director   May 14, 2018
Maged Shenouda        

 

 4 

 

  

INDEX TO EXHIBITS

 

Exhibit No.   Description
3.1   Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-1 filed with the SEC on November 13, 2012).
3.2   Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Report on Form 8-K filed with the SEC on May 19, 2014).
3.3   Nevada Certificate of Amendment to Articles of Incorporation, effective May 30, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on May 27, 2014).
3.4   Nevada Certificate of Amendment to Articles of Incorporation, effective July 8, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on July 14, 2014).
3.5   Nevada Certificate of Amendment to Articles of Incorporation, effective February 12, 2015 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed with the SEC on February 13, 2015).
3.6   Nevada Certificate of Change Pursuant to NRS 78,209, effective August 11, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on August 10, 2015).
3.7   Amended and Restated Bylaws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 of Relmada’s Form 8-K filed with the SEC on August 7, 2015).
4.1   Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Form S-8 filed on October 10, 2015).
5.1     Opinion of Fennemore Craig, P.C. *
23.1   Consent of GBH CPAs, PC *
23.2   Consent of Fennemore Craig, P.C. (included in Exhibit 5.1) *
24.1   Power of Attorney (included on signature page) *
99.1   Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.14 of Relmada’s Form S-1/A filed with the SEC on December 9, 2014).
99.2   Amended 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of Relmada’s Form 8-K filed with the SEC on August 7, 2015).
99.3   Amendment No. 2 to Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan  (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on February 2, 2017).
99.4   Third Amendment to the 2014 Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on May 14, 2018).

  

* Filed herewith

 

 

5

 

 

 EX-5.1 2 fs82018ex5-1_relmada.htm OPINION OF FENNEMORE CRAIG, P.C

Exhibit 5.1

 

 

300 E. Second Street, Suite 1510
Reno, NV 89501

PH (775) 788-2200 | FX (775) 786-1177

fennemorecraig.com

 

 

 

 

 

May 14, 2018

 

Relmada Therapeutics, Inc.

757 Third Avenue, Suite 2018

New York, New York 10017

 

Ladies and Gentlemen:

 

You have requested our opinion with respect to certain matters in connection with the registration under the Securities Act of 1933, as amended (the “Act”), by Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), by means of a registration statement on Form S-8 (as it may be amended and supplemented, the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) relating to the registration of 5,000,000 shares (the “Future Stock”) of common stock, par value $0.001 per share of the Company (the “Common Stock”), issuable pursuant to the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”).

 

In connection with this opinion, we have examined and relied upon (i) the Registration Statement, (ii) the Plan and (iii) the Company’s Articles of Incorporation and Bylaws, each as amended and currently in effect, and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have examined originals or copies of such other corporate records, certificates of corporate officers and public officials and other agreements and documents as we have deemed necessary or advisable for purposes of this opinion letter. We have relied upon the certificates of all public officials and corporate officers with respect to the accuracy of all factual matters contained therein.

 

On the basis of the foregoing, and in reliance thereon, we are of the opinion that when Future Shares are issued pursuant to the Plan or pursuant to stock options or other instruments that have been issued pursuant to the Plan, such Future Shares will be validly issued, fully paid and nonassessable.

 

With respect to the Future Shares, we have assumed that at the time of issuance, the Corporation has sufficient authorized, but unissued shares available to allow for such issuance.

 

 

 

 

 

Relmada Therapeutics, Inc.

May 14, 2018

Page 2

 

The opinions expressed above are limited to the laws of the State of Nevada, including reported judicial decisions. This Opinion Letter is intended solely for use in connection with the registration and offering of the Common Stock as described in the Registration Statement and resales of the Common Stock, and it may not be reproduced or filed publicly, without the written consent of this firm; provided, however, we hereby consent to the filing of this Opinion Letter as an exhibit to the Registration Statement and to the use of our name under the heading “Legal Matters” contained in the Prospectus included in the Registration Statement. In giving this consent, we do not hereby admit that we are in a category of persons whose consent is required pursuant to Section 7 of the Securities Act of 1933 or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

 

  Very truly yours,
   
  /s/ Fennemore Craig, P.C.
   
  Fennemore Craig, P.C.

 

 

 

 

 EX-23.1 3 fs82018ex23-1_relmada.htm CONSENT OF GBH CPAS, PC

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of our report dated September 28, 2017 relating to the consolidated financial statements of Relmada Therapeutics, Inc. as of June 30, 2017 and 2016 and for each of the years then ended.

/s/ GBH CPAs, PC

GBH CPAs, PC

www.gbhcpas.com

Houston, Texas

May 14, 2018

 GRAPHIC 4 ex5-1_001.jpg GRAPHIC begin 644 ex5-1_001.jpg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end